DNL747

DRUG2 trials

Sponsors

Denali Therapeutics Inc., Sanofi

Conditions

Alzheimer DiseaseAmyotrophic Lateral Sclerosis

Phase 1

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

TerminatedNCT03757351

SanofiAmyotrophic Lateral Sclerosis

Start: 2018-12-14End: 2020-06-18Updated: 2025-09-22

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

CompletedNCT03757325

Denali Therapeutics Inc.Alzheimer Disease

Start: 2019-02-13End: 2019-12-05Updated: 2020-02-26

Related Papers

Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants

Clinical and Translational Science2023-11-2826 citations

Safety, pharmacokinetics and target engagement of novel <scp>RIPK1</scp> inhibitor <scp>SAR443060</scp> (<scp>DNL747</scp>) for neurodegenerative disorders: Randomized, <scp>placebo‐controlled</scp>, <scp>double‐blind</scp> phase I/Ib studies in healthy subjects and patients

Clinical and Translational Science2022-06-0184 citations